Table 1.
MiRNA expression in radiation response in prostate cancer cell lines. With regard to the data presented from our study, the results of the 3rd day of the study, i.e., 3 × 2.5 Gy, were taken into account.
| miRNA | Cell Line Used in the Literature | Function | Target | miRNA Expression after Irradiation | Functional Role | Therapeutic Strategy | References | |
|---|---|---|---|---|---|---|---|---|
| In the Literature (2–8 Gy) |
Our Study (3 × 2.5 Gy) |
|||||||
| hsa-miRNA-95 | PC3 | - | SGPPI | ↑ (6 Gy) | ↑ PC3, LNCaP, HPrEPiC↓ DU145 |
RR | Antagomirs | [28,29] |
| hsa-miRNA-106b | LNCaP | OM | P21 P53 Caspase-7 |
↓ (6 Gy) | ↑ PC3, LNCaP, HPrEPiC ↓ DU145 |
RR | Antagomirs | [30,31] |
| hsa-miRNA-145 | LNCaP, PC3 | TS | DNMT3b SPOP ZEB1 |
↑ (2 Gy) | ↑ PC3, DU145, HPrEPiC ↓ LNCAP |
RR | Mimicking | [32,33,34,35,36] |
| hsa-miRNA-541-3p | LNCaP, DU145, PC3, and PrEC | TS | HSP27 | ↑ (2–8 Gy) | ↑ PC3, LNCaP, HPrEPiC ↓ DU145 |
RR | Mimicking | [37] |
TS—Tumor suppressor miRNA; OM—Oncogenic miRNAs; RR—Radioresistant; RS—Radiosensitive; -—absent of information; ↑—increased expression; ↓—decreased expression.